Evidence map›Paper›PMID 31188200›Full record

Trial reportAnnals of surgery2020

Survival Following Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastases.

Svein Dueland, Trygve Syversveen, Jon Magnus Solheim, Steinar Solberg, Harald Grut, Bjørn Atle Bjørnbeth, Morten Hagness, Pål-Dag Line

Registry-linked trialAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Annals of surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05186116 (Living Donor Liver Transplantation), which is not on this map. Cited by 152 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
152citing papers in PubMed, 7 pooled it
18.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05186116 narecruitingnot on this mapstarted 2022, after this paper: background citation

Living Donor Liver Transplantation (LDLT) in Non Resectable Colo-rectal Cancer Liver Metastasis. The LIVERMORE Trial (LIVing Donor livEr tRansplant Modena cOloRectal mEtastasis) [Original Title in Italian: "Trapianto di Fegato da Donatore Vivente Per Metastasi Epatiche Non Resecabili da Adenocarcinoma Del Colon"]

TypeinterventionalSponsorAzienda Ospedaliero-Universitaria di ModenaRan2022 to 2032Enrolled25ConditionsColon Adenocarcinoma, Liver Metastasis Colon CancerArmsLiving donor liver transplant, Split liver transplant, RAPID, DDLT
3 · Its place in the literature

Who cites it

152 citing papers in PubMed, 7 syntheses or guidelines pooled it, 328 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

92 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Svein DuelandExperimental Transplantation and Malignancy Research Group, Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital, Oslo, Norway.
Trygve SyversveenDepartment of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Jon Magnus SolheimSection for Transplantation Surgery, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.
Steinar SolbergDepartment of Thoracic Surgery, Oslo University Hospital, Oslo, Norway.
Harald GrutDepartment of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Bjørn Atle BjørnbethDepartment of Hepatobiliary Surgery, Oslo University Hospital, Oslo, Norway.
Morten HagnessSection for Transplantation Surgery, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.
Pål-Dag LineSection for Transplantation Surgery, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.
Oslo University Hospital · NOUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine overall survival and disease-free survival in selected patients with nonresectable liver-only colorectal cancer receiving liver transplantation.

backgroundPatients with nonresectable colorectal cancer receiving palliative chemotherapy has a 5-year overall survival of about 10%. Liver transplantation provided an overall survival of 60% in a previous study (SECA-I). Risk factors for death were carcinoembryonic antigen (CEA) >80 μg/L, progressive disease on chemotherapy, size of largest lesion>5.5 cm, and less than 2 years from resection of the primary tumor to transplantation.

methodsIn this prospective (SECA-II) study, we included colorectal cancer patients with nonresectable liver-only metastases determined by computed tomography (CT)/magnetic resonance imaging/positron emission tomography scans and at least 10% response to chemotherapy. Time from diagnosis to liver transplant was required to be more than 1 year.

resultsAt a median follow-up of 36 months, Kaplan-Meier overall survival at 1, 3, and 5 years were 100%, 83%, and 83%, respectively. Disease-free survival at 1, 2, and 3 years were 53%, 44%, and 35%, respectively. Overall survival from time of relapse at 1, 2, and 4 years were 100%, 73%, and 73%, respectively. Recurrence was mainly slow growing pulmonary metastases amenable to curative resection. Fong Clinical Risk Score of 1 to 2 at the time of diagnosis resulted in longer disease-free survival than score 3 to 4 (P = 0.044). Patients included in the present study had significantly better prognostic factors than the previous SECA-I study.

conclusionLiver transplantation provides the longest overall survival reported in colorectal cancer patient with nonresectable liver metastases. Improved selection criteria give patients with nonresectable colorectal liver metastases a 5-year overall survival comparable to other indications for liver transplantation.

Indexed as

AdultAgedAntineoplastic AgentsBiomarkers, TumorCarcinoembryonic AntigenColorectal NeoplasmsDisease-Free SurvivalDisease ProgressionFemaleHumansLiver NeoplasmsLiver TransplantationMaleMiddle AgedProspective StudiesRisk FactorsAntineoplastic AgentsBiomarkers, TumorCarcinoembryonic Antigen

Identifiers

PMID31188200
OpenAlexW2949178835

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.